Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials

IMPORTANCE: The optimal sequencing of immune checkpoint inhibitors and targeted therapy for BRAF V600E/K-mutant melanoma is not well established. OBJECTIVE: To assess the association of BRAF wild-type (WT) or BRAF V600E/K-mutant status and BRAF inhibitor (BRAFi) with or without MEK inhibitor (MEKi)...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Puzanov, Igor, Ribas, Antoni, Robert, Caroline, Schachter, Jacob, Nyakas, Marta, Daud, Adil, Arance, Ana, Carlino, Matteo S., O’Day, Steven J., Long, Georgina V., Margolin, Kim A., Dummer, Reinhard, Schadendorf, Dirk, Lutzky, Jose, Ascierto, Paolo A., Tarhini, Ahmad, Lin, Jianxin, Mogg, Robin, Homet Moreno, Blanca, Ibrahim, Nageatte, Hamid, Omid
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2020
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7366279/
https://ncbi.nlm.nih.gov/pubmed/32672795
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.2288
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados